

Centers for Medicare & Medicaid Services: Proposed Medicare Hospital Outpatient Payment Rates and Policies for CY 2027

On July 7, 2026, the Centers for Medicare & Medicaid Services (CMS) released a proposed rule updating Medicare payment rates and policies under the hospital outpatient prospective payment system (OPPS) for calendar year 2027. CMS proposed to increase Medicare payment rates by 2.4 percent for hospital outpatient services and ambulatory surgical centers (ASCs) that meet quality reporting requirements. CMS calculated that when compared to estimated CY 2026 payments, the proposed update, combined with other proposed payment policies, will result in an overall increase to OPPS providers of approximately \$9.5 billion and an increase to ASCs of approximately \$9.9 billion.

CMS released an accompanying [fact sheet](#) that outlines key provisions in the proposed rule. Examples of proposed policy changes that would impact hospitals include lowering payments for certain imaging services done at off-campus hospital clinics to the payment rates received for the services when furnished in a doctor's office; significantly reducing payments to hospitals for drugs acquired through the 340B program; expediting the applicability of a payment reduction for non-drug items and services; updating validation and validation appeals procedures for digital quality measures; and removing 638 more services from the "inpatient only" list, which will allow for the services to be paid by Medicare in the hospital outpatient setting when clinically appropriate.

However, providers subject to the 340B remedy offset will see an estimated \$2.3 billion reduction in CY 2027 payments. Comments are due to CMS on August 31, 2026.

Proposed Payment Policies for Blood and Blood Products

CMS proposes to continue using the blood-specific cost-to-charge ratio (CCR) methodology, in place since 2005, to establish separate payment rates for blood and blood products through ambulatory payment classifications (APCs). The CCR methodology utilizes actual or simulated CCRs from recently available hospital cost reports to convert hospital charges for blood and blood products to costs. This methodology accounts for the unique charging and cost accounting structures of individual hospitals and reflects actual blood product acquisition and processing costs.

CMS also proposes to continue applying the blood-specific CCR methodology for calculating the reported costs of blood and blood products appearing on claims with services assigned to comprehensive ambulatory payment classifications (C-APCs). When blood and blood products appear on the same claims as services assigned to C-APCs, CMS proposes not to make separate payments for blood and blood products, as their costs are included in the overall C-APC payment.

CMS proposes to establish variable payment rates for blood and blood products based on CY 2025 claims data and current APC weighting policy. The proposed payment rates for blood and blood products are listed in Table 1.

Proposed Payment Policies and Rates for Transfusion, Apheresis, Stem Cell Procedures, and Transfusion Laboratory Services

For CY 2027, CMS proposes to establish variable payment rates for transfusion, apheresis, and stem cell procedures. The proposed payment rates are detailed in Table 2.

CMS also proposes to adjust payment rates for transfusion laboratory services covered under the OPPS, which are summarized in Table 3.

Proposed Payment Policies for Cell and Gene Therapies

CMS proposes to continue the policy finalized in CY 2025, which excludes cell and gene therapies from C-APC packaging when those therapies are not functioning as integral, ancillary, supportive, dependent, or adjunctive to the primary C-APC service. When cell and gene therapies are administered, they represent the primary treatment being provided and therefore qualify for separate payment rather than being packaged into a comprehensive service payment.

For CY 2027 and subsequent years, new cell and gene therapy products with product-specific HCPCS codes will continue to be added to the C-APC exclusion list to ensure appropriate separate payment as primary therapeutic interventions.

CMS' proposed payment rates for cell and gene therapies are listed in Table 4.

Comprehensive APC (C-APC) Policy Continuation

CMS proposes to continue the C-APC payment policy, which packages adjunctive and secondary items, services, and procedures into the costliest primary procedure at the claim level. No new C-APCs are proposed for CY 2027; the total number of C-APCs remains at 74. The policy continues to exclude certain categories of services from packaging, such as cell and gene therapies that are not integral to the primary C-APC service; services assigned to New Technology APCs; drugs and biologicals described by HCPCS code C9399 (Unclassified Drugs or Biologicals).

For questions or to provide feedback on this summary, contact: advocacy@aabb.org

Centers for Medicare & Medicaid Services Proposed CY 2027 Hospital Outpatient Payment Rates, Compared to CY 2026 Final Rates

Table 1. Blood and Blood Products

HCPCS Code	Short Descriptor	SI	APC	CY2026 Final Payment	CY2027 Proposed Payment	\$ Change	% Change
P9010	Whole blood for transfusion	R	9510	\$189.84	\$284.38	+\$94.54	+49.8%
P9011	Blood split unit	R	9520	\$155.84	\$177.76	+\$21.92	+14.1%
P9012	Cryoprecipitate each unit	R	9511	\$71.95	\$82.42	+\$10.47	+14.6%
P9016	Rbc leukocytes reduced	R	9512	\$184.91	\$206.46	+\$21.55	+11.7%
P9017	Plasma 1 donor frz w/in 8 hr	R	9508	\$85.98	\$96.83	+\$10.85	+12.6%
P9019	Platelets, each unit	R	9515	\$53.17	\$91.38	+\$38.21	+71.9%
P9020	Platelet rich plasma unit	R	9516	\$559.79	\$560.98	+\$1.19	+0.2%
P9021	Red blood cells unit	R	9517	\$150.57	\$169.49	+\$18.92	+12.6%
P9022	Washed red blood cells unit	R	9518	\$368.58	\$388.22	+\$19.64	+5.3%
P9023	Frozen plasma, pooled, sd	R	9509	\$55.96	\$96.90	+\$40.94	+73.2%
P9025	Plasma cryo redu path each	R	9538	\$133.76	\$144.25	+\$10.49	+7.8%
P9026	Cryo fib comp path redu each	R	9539	\$549.28	\$533.06	\$-16.22	-3.0%
P9027	Rbc o2 co2 reduced	R	9541	\$511.59	\$584.87	+\$73.28	+14.3%
P9031	Platelets leukocytes reduced	R	9526	\$144.26	\$153.32	+\$9.06	+6.3%
P9032	Platelets, irradiated	R	9500	\$392.97	\$399.62	+\$6.65	+1.7%
P9033	Platelets leukoreduced irradiated	R	9521	\$189.59	\$215.75	+\$26.16	+13.8%
P9034	Platelets, pheresis	R	9507	\$308.96	\$465.08	+\$156.12	+50.5%
P9035	Platelet pheres leukoreduced	R	9501	\$511.59	\$584.87	+\$73.28	+14.3%
P9036	Platelet pheresis irradiated	R	9502	\$949.13	\$752.51	\$-196.62	-20.7%
P9037	Plate pheres leukoredu irradiated	R	9530	\$680.61	\$786.56	+\$105.95	+15.6%
P9038	Rbc irradiated	R	9505	\$145.22	\$167.60	+\$22.38	+15.4%

HCPCS Code	Short Descriptor	SI	APC	CY2026 Final Payment	CY2027 Proposed Payment	\$ Change	% Change
P9039	Rbc deglycerolized	R	9504	\$313.00	\$509.79	+\$196.79	+62.9%
P9040	Rbc leukoreduced irradiated	R	9522	\$265.41	\$299.31	+\$33.90	+12.8%
P9043	Plasma protein fract,5%,50ml	R	9514	\$8.11	\$8.74	+\$0.63	+7.8%
P9044	Cryoprecipitatereducedplasma	R	9523	\$132.05	\$70.27	\$-61.78	-46.8%
P9048	Plasmaprotein fract,5%,250ml	R	9519	\$35.32	\$38.11	+\$2.79	+7.9%
P9050	Granulocytes, pheresis unit	E2		<i>Not paid by Medicare when submitted on outpatient claims (any outpatient bill type).</i>			
P9051	Blood, l/r, cmv-neg	R	9524	\$151.58	\$192.60	+\$41.02	+27.1%
P9052	Platelets, hla-m, l/r, unit	R	9525	\$708.06	\$629.99	\$-78.07	-11.0%
P9053	Plt, pher, l/r cmv-neg, irr	R	9531	\$503.45	\$604.64	+\$101.19	+20.1%
P9054	Blood, l/r, froz/degly/wash	R	9527	\$265.19	\$361.00	+\$95.81	+36.1%
P9055	Plt, aph/pher, l/r, cmv-neg	R	9528	\$250.49	\$300.19	+\$49.70	+19.8%
P9056	Blood, l/r, irradiated	R	9529	\$84.55	\$84.33	\$-0.22	-0.3%
P9057	Rbc, frz/deg/wsh, l/r, irradi	R	9532	\$422.69	\$434.21	+\$11.52	+2.7%
P9058	Rbc, l/r, cmv-neg, irradi	R	9533	\$249.40	\$323.14	+\$73.74	+29.6%
P9059	Plasma, frz between 8-24hour	R	9513	\$73.77	\$88.50	+\$14.73	+20.0%
P9060	Fr frz plasma donor retested	R	9503	\$53.25	\$54.29	+\$1.04	+2.0%
P9070	Pathogen reduced plasma pool	R	9534	\$55.78	\$51.17	\$-4.61	-8.3%
P9071	Pathogen reduced plasma sing	R	9535	\$294.48	\$134.40	\$-160.08	-54.4%
P9073	Platelets pheresis path redu	R	9536	\$607.43	\$647.04	+\$39.61	+6.5%
P9099	Blood component/product noc	R	9537	\$35.32	\$51.17	+\$15.85	+44.9%
P9100	Pathogen test for platelets	S	5733	\$60.27	\$66.91	+\$6.64	+11.0%
C9507	Covid-19 convalescent plasma	R	9540	\$680.03	\$424.18	\$-255.85	-37.6%

Table 2. Transfusion, Apheresis, and Stem Cell Procedures

HCPCS Code	Short Descriptor	SI	APC	CY2026 Final Payment	CY2027 Proposed Payment	\$ Change	% Change
36430	Transfusion bld/bld compnt	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
36440	Bld push tfuj 2 yr/<	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
36450	Bld exchange truj newborn	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
36455	Bld exchange truj oth thn nb	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
36456	Prtl exchange transfuse nb	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
36460	Intrauterine transfusion ftl	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
36511	Apheresis wbc	S	5242	\$1,591.16	\$1,807.56	+\$216.40	+13.6%
36512	Apheresis rbc	S	5242	\$1,591.16	\$1,807.56	+\$216.40	+13.6%
36513	Apheresis platelets	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
36514	Apheresis plasma	S	5242	\$1,591.16	\$1,807.56	+\$216.40	+13.6%
36516	Apheresis immunoads slctv	S	5243	\$4,449.84	\$4,866.48	+\$416.64	+9.4%
36522	Photopheresis	S	5243	\$4,449.84	\$4,866.48	+\$416.64	+9.4%
38205	Harvest allogeneic stem cell	B		<i>Not paid under OPPS</i>			
38206	Harvest auto stem cells	S	5242	\$1,591.16	\$1,807.56	+\$216.40	+13.6%
38207	Cryopreserve stem cells	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
38208	Thaw preserved stem cells	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
38209	Wash harvest stem cells	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
38210	T-cell depletion of harvest	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
38211	Tumor cell deplete of harvst	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
38212	Rbc depletion of harvest	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
38213	Platelet deplete of harvest	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
38214	Volume deplete of harvest	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%
38215	Harvest stem cell concentrte	S	5241	\$450.73	\$510.12	+\$59.39	+13.2%

HCPCS Code	Short Descriptor	SI	APC	CY2026 Final Payment	CY2027 Proposed Payment	\$ Change	% Change
38220	Dx bone marrow aspirations	J1	5072	\$1,687.37	\$1,896.52	+\$209.15	+12.4%
38221	Dx bone marrow biopsies	J1	5072	\$1,687.37	\$1,896.52	+\$209.15	+12.4%
38222	Dx bone marrow bx & aspir	J1	5073	\$2,967.63	\$3,320.17	+\$352.54	+11.9%
38225	Car-t hrv bld-driv t lymphcyt	B		<i>Not paid under OPPS</i>			
38226	Car-t prep t lymphcyt f/trns	B		<i>Not paid under OPPS</i>			
38227	Car-t receipt&prepj admn	B		<i>Not paid under OPPS</i>			
38228	Car-t admn autologous	S	5694	\$337.46	\$368.83	+\$31.37	+9.3%
38230	Bone marrow harvest allogeneic	S	5242	\$1,591.16	\$1,807.56	+\$216.40	+13.6%
38232	Bone marrow harvest autolog	S	5243	\$4,449.84	\$4,866.48	+\$416.64	+9.4%
38240	Transplt allo hct/donor	J1	5244	\$64,263.52	\$75,722.17	+\$11,458.65	+17.8%
38241	Transplt autol hct/donor	S	5242	\$1,591.16	\$1,807.56	+\$216.40	+13.6%
38242	Transplt allo lymphocytes	S	5242	\$1,591.16	\$1,807.56	+\$216.40	+13.6%
38243	Transplj hematopoietic boost	S	5242	\$1,591.16	\$1,807.56	+\$216.40	+13.6%
88184	Flowcytometry/ tc 1 marker	Q2	5673	\$366.21	\$402.02	+\$35.81	+9.8%
88185	Flowcytometry/tc add-on	N		<i>Paid under OPPS; payment is packaged into payment for other services. Therefore, there is no separate APC payment.</i>			
88187	Flowcytometry/read 2-8	B		<i>Not paid under OPPS.</i>			
88188	Flowcytometry/read 9-15	B		<i>Not paid under OPPS.</i>			
88189	Flowcytometry/read 16 & >	B		<i>Not paid under OPPS.</i>			

Table 3. Transfusion Laboratory Services

HCPCS Code	Short Descriptor	SI	APC	CY2026 Final Payment	CY2027 Proposed Payment	\$ Change	% Change
86850	Rbc antibody screen	Q1	5671	\$53.24	\$57.64	+\$4.40	+8.3%
86860	Rbc antibody elution	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86870	Rbc antibody identification	Q2	5673	\$366.21	\$402.02	+\$35.81	+9.8%
86880	Coombs test direct	Q1	5734	\$60.27	\$152.43	+\$92.16	+152.9%
86885	Coombs test indirect qual	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86886	Coombs test indirect titer	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86890	Autologous blood process	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86891	Autologous blood op salvage	Q1	5674	\$823.13	\$992.87	+\$169.74	+20.6%
86900	Blood typing serologic abo	Q1	5734	\$135.93	\$152.43	+\$16.50	+12.1%
86901	Blood typing serologic rh(d)	Q1	5732	\$38.16	\$41.98	+\$3.82	+10.0%
86902	Blood type antigen donor ea	Q1	5673	\$366.21	\$402.02	+\$35.81	+9.8%
86904	Blood typing patient serum	Q1	5733	\$60.27	\$66.91	+\$6.64	+11.0%
86905	Blood typing rbc antigens	Q1	5673	\$366.21	\$402.02	+\$35.81	+9.8%
86906	Bld typing serologic rh phnt	Q1	5732	\$38.16	\$41.98	+\$3.82	+10.0%
86920	Compatibility test spin	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86921	Compatibility test incubate	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86922	Compatibility test antiglob	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86923	Compatibility test electric	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86927	Plasma fresh frozen	S	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86930	Frozen blood prep	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86931	Frozen blood thaw	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86932	Frozen blood freeze/thaw	Q1	5732	\$38.16	\$41.98	+\$3.82	+10.0%
86945	Blood product/irradiation	Q1	5732	\$38.16	\$41.98	+\$3.82	+10.0%

HCPCS Code	Short Descriptor	SI	APC	CY2026 Final Payment	CY2027 Proposed Payment	\$ Change	% Change
86950	Leukocyte transfusion	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86960	Vol reduction of blood/prod	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86965	Pooling blood platelets	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86970	Rbc pretx incubatj w/chemicl	Q1	5733	\$60.27	\$66.91	+\$6.64	+11.0%
86971	Rbc pretx incubatj w/enzymes	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86972	Rbc pretx incubatj w/density	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86975	Rbc serum pretx incubj drugs	Q1	5735	\$456.40	\$487.07	+\$30.67	+6.7%
86976	Rbc serum pretx id dilution	Q1	5731	\$29.55	\$30.21	+\$0.66	+2.2%
86977	Rbc serum pretx incubj/inhib	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86978	Rbc pretreatment serum	Q1	5733	\$60.27	\$66.91	+\$6.64	+11.0%
86985	Split blood or products	Q1	5672	\$174.06	\$198.18	+\$24.12	+13.9%
86999	Unlisted transfusion med px	Q1	5731	\$29.55	\$30.21	+\$0.66	+2.2%

Table 4. CAR T-Cell Therapies

HCPCS Code	Short Descriptor	Trade Name	SI	APC	CY2026 Final Payment	CY2027 Proposed Payment	\$ Change	% Change
Q2041	Axicabtagene ciloleucel car+	Yescarta	K	9035	\$533,230.17	\$531,849.12	\$-1,381.05	-0.3%
Q2042	Tisagenlecleucel car-pos t	Kymriah	K	9194	\$591,726.20	\$614,180.81	+\$22,454.61	+3.8%
Q2043	Sipuleucel-t auto cd54+	Provenge	K	9273	\$55,272.32	\$56,269.19	+\$996.87	+1.8%
Q2053	Brexucabtagene car pos t	Tecartus	K	9391	\$489,304.61	\$489,290.60	\$-14.01	0.0%
Q2054	Lisocabtagene mara car pos t	Breyanzi	K	9413	\$562,538.19	\$562,260.84	\$-277.35	0.0%
Q2055	Idecabtagene vicleucel car	Abecma	K	9422	\$557,317.93	\$559,781.08	+\$2,463.15	+0.4%
Q2056	Ciltacabtagene car-pos t	CARVYKTI	K	9498	\$565,868.95	\$588,494.81	+\$22,625.86	+4.0%
Q2057	Afamitresgene autoleucel	Tecelra	G	2067	\$770,620.00	\$770,620.00	\$0.00	0.0%
Q2058	Obechtge autol up to 400 mil	Aucatzyl	G	0831	\$278,250.00	\$278,250.00	\$0.00	0.0%
J3387	Inj elivaldogene autotemecel	Skysona	K	0906		\$3,180,000		
J3391	Inj, atidarsagene autotemcel	Lenmeldy	K	0845		\$4,505,000		
J3392	Inj, exagamglogene autotem	CASGEVY	K	0824		\$2,332,000		
J3398	Inj luxturna 1 billion vec g	Luxturna	K	9070		\$3,070.089		
J3399	Inj onase abepar-xioi treat	Zolgensma	K	9141		\$2,587,087		

HCPCS Code	Short Descriptor	Trade Name	SI	APC	CY2026 Final Payment	CY2027 Proposed Payment	\$ Change	% Change
J3402	Inj. remestemcel-l-rknd/ td	Ryoncil	K	0886		\$202,713		
J1411	Inj, hemgenix, per tx dose	Hemgenix	K	9138		\$3,691,450		